IMPORTANCE OF LYT-2+ T-CELLS IN THE RESISTANCE OF MELPHALAN-CURED MOPC-315 TUMOR BEARERS TO A CHALLENGE WITH MOPC-315 TUMOR-CELLS

  • 1 September 1988
    • journal article
    • research article
    • Vol. 48  (17) , 4834-4842
Abstract
We have previously shown that mice bearing a large MOPC-315 tumor can be cured by a low dose of melphalan (L-phenylalanine mustard; L-PAM) if T-cell-dependent antitumor immunity also aids in tumor eradication (S. Ben-Efrain et al., Cancer Immunol. Immunother., 15: 101-107, 1983). Here we describe the phenotype of the T-cells that are responsible for the potent antitumor immunity exhibited by the L-PAM cured MOPC-315 tumor bearers. Initially, we identified the subset of T-cells responsible for the ability of spleen cells from L-PAM-cured MOPC-315 tumor bearers to neutralize tumor growth in the local adoptive transfer assay. The tumor-neutralizing activity of spleen cells from L-PAM-cured tumor bearers was drastically reduced when the spleen cells were depleted either in vitro or in vivo of Lyt-2+ cells. On the other hand, the tumor-neutralizing activity of spleen cells from L-PAM-cured MOPC-315 tumors bearers was not reduced, but actually enhanced, when the spleen cells were depleted either in vitro or in vivo of L3T4+ cells. The Lyt-2+ T cells, and not the L3T4+ T-cells, were also found to be important for the ability of the intact L-PAM-cured MOPAC-315 tumor bearers to reject a challenge with MOPC-315 tumor cells. Specifically, treatment of L-PAM-cured MOPC-315 tumor bearers with monoclonal anti-Lyt-2.2 antibody drasticallyreduced the ability of the mice to reject the tumor challenge. In contrast, treatment of L-PAM-cured MOPC-315 tumor bearers with monoclonal anti-L3T4 antibody did not interfere with the ability of the mice to reject the tumor challenge, yet the same protocol of anti-L3T4 antibody treatment abolished the ability of splenic T-cells to provide help for the generation of a primary T-cell-dependent antibody response. The resistance of the L-PAM-cured MOPC-315 tumor bearers to challenge with MOPC-315 tumor cells was also dependent on the participation of carrageenan-sensitive effector cells, most likely macrophages, in tumor eradication. However, the immunity mediated by the T-cells, independent of caraageenan-sensitive effector cells, was extremely powerful and sufficient for the rejection of a tumor challenge with at least 300-fold, and possibly even 3000-fold, the minimal lethal dose of MOPC-315 tumor cells for 100% of normal mice. Consequently, in order to illustrate the importance of carrageenan-sensitive effector cells in the resistance of the L-PAM-cured MOPC-315 tumor bearers to tumor challenge, it was necessary to increase the challenge inoculum to 30,000-fold the minimal lethal dose of tumor cells so as to surpass the challenge inoculum that can be rejected by T-cell-dependent immunity in the absence of carrageenan-sensitive effector cells.

This publication has 27 references indexed in Scilit: